|A+ Science AB|
|Slogan||Research coming alive|
|Key people||Anna Fröling (CEO & CFO) |
|Number of employees||25|
|Related Certifications||Certificate in Current Pharmacovigilance Regulatory Landscape|
A+ Science is a Nordic Contract Research Organisation which provides its clinical services, customized pharmacovigilance solution or support within specific pharmacovigilance function, outsourcing and Site Management Organization (SMO) to pharmaceutical, generic, biotech and medical device companies, clinical research organisations (CROs) and individual academic researchers. Clinical services are focused on pharmaceutical (Phase I-IV) multinational clinical trials, small complex trials, non-interventional trials, registry trials and medical device studies within several different therapeutic areas. With a proven track record, a large network of investigators and a well-established process for the conduct of clinical trials, the company put you in control of the clinical development and help customers shorten time to market.A+ Science is headquartered in Stockholm, Sweden, with running operations across Nordic countries as well as Nothern Europe. The majority of the company's ownership, 81%, belongs to the company's employees. 
- 1997 - The company was founded as a subsidiary of Gothenburg University by clinical experts within the cardiovascular field, Björn Dahlöf, Peter Held, Åke Hjalmarsson, Olle Isaksson and Karl Swedbergas. It was formed as a result of an idea about clinical trial study named ASCOT, which was realized with 20,000 patients from five countries, and published results led to significant changes in the guiding principles and in the treatment of cardiovascular diseases. 
- December 12, 2001 - A+ Science Invest AB, InnovationsKapital and Swedestart have invested 45 million SEK in the research company Pharmacore AB enhance Pharmacore's development of a new cluster of pharmaceuticals for the treatment of common medical conditions, such as gastritis, functional gastrointestinal complaints, and cardiovascular diseases, such as high blood pressure and heart failure. 
- January 1, 2003 - Office was opened in Stockholm, Sweden because the company’s customers were located mostly there.
- 2003 - The part of the ASCOT study was stopped because its results and benefits were published in the Lancet. In this year company conducted another multinational study named ACCOMPLISH in collaboration with several world largest pharmaceutical companies.
- 2004 - A+ Science started the collaboration with Sahlgrenska Academy, the University of Gothenburg on a project Continuing Medical Education (CME), which are organized educational sessions for physicians, by assisting in accreditation procedures and providing educational material of a medical nature. The company started to offer the outsourcing services to the market, and thereby provide short and long-term solutions to companies in need of in-sourced consultants.
- 2006 - The company became public by listing on the stock exchange “Aktietorget” through Vita Nova Ventures AB and the organization expanded with 55 employees and with the comprehensive network of study sites with physicians throughout and beyond the Nordic countries. In the same year, the company acquired Northern Sweden Clinical Research Institute AB (NS-CRI), experienced with clinical trials in oncology, and Sedoc Pharmaceutical Medicine AB, specialized in conduction phase I and II studies, with offices in Stockholm and Lund. 
- August 31, 2007 - Vita Nova Ventures AB took over SEDOC Pharmaceutical Medicine AB and added SEDOC to its clinical research division which included after that acquisition A+ Science AB, SEDOC Pharmaceutical Medicine AB, and Northern Clinical Research Institute AB, with approx. 80 employees, and which continued to operate under the name A+ Science with offices in Gothenburg, Stockholm, Lund and Umeå. 
- June 25, 2008 - A+ Science AB, the subsidiary company of Vita Nova Ventures acquired part of the business activities in the bankrupt estate of NMCT AB in Gothenburg and formed new established subsidiary company A+ Science Enrolment AB in order to facilitate patient recruitment in clinical trials through media and computerized support, logistics programs and a unique patient database. NMCT personnel, databases, and technical equipment moved to the Gothenburg office. 
- June 02, 2008 - A+ Science’s two Stockholm offices merged into one and moved in the Solna Business Park. 
- February 04, 2008 - The company extended its services by launching new Clinical Pharmaceutical Research unit in Stockholm called City Site equipped to conduct clinical trials within many different therapeutic fields. 
- September 13, 2010 - The company became a network partner to Swedish Medtech, the Association for Medical Technology in Sweden. 
- December 17, 2010 - Agneta Franksson resigned from CEO position and Håkan Gartell, which was previously CEO of Vita Nova Ventures AB (Publ), took her place. 
- March 01, 2011 Ulf Skough has been appointed as CEO of A + Science AB. 
- 2012 - the subsidiaries A+ Science AB, A+ Science Stockholm AB and Scandinavian CRI Holding AB have merged into A+ Science Holding AB to simplify the structure of the company. Today A+ Science Holding is named A+ Science AB. The company shut down the office in Gothenburg and business was transferred to the Stockholm office. 
- September 1, 2012 - Anna Fröling became CFO. 
- December 2013 - A+ Science became company run by by its employees. 
- June 27, 2014 - Anna Fröling became Chief Executive Officer (CEO) of A+ Science AB. 
- May 26, 2015 - The company offered the translation of Finnish pharmacovigilance and regulatory documents local literature search in Finland as new services. 
Services and therapeutic areas
|Therapeutic areas ||
Top 5 Recent Tweets
|June 20, 2018||RonaldKlain||While the world was looking elsewhere, Trump repealed Obama's ocean policy yesterday, and put in place a new, anti-… https://t.co/Vz1kbxoT7p|
|June 20, 2018||MsPackyetti||A family concentration camp is still a concentration camp.
• •In my freshman political science seminar, we learned… https://t.co/ho99fhn56d
|June 19, 2018||SenBobCasey||Separating migrant children from their parents is a policy straight from the pit of hell. https://t.co/678F8KTKPk|
|June 21, 2018||TruePalestinia2||Scientists at Israel’s Technion have developed a system for the selective nanoscale transport of the chemotherapeut… https://t.co/SaaBtvE91c|
|June 20, 2018||smolkjd||tell me he doesn't look like the mysterious guy who turns up in a disaster science fiction movie ready to save your… https://t.co/rbe55lXyhL|
Top 5 Recent News Headlines
Top 5 Lifetime Tweets
Top 5 Lifetime News Headlines
- February 20, 2010 - ACCOMPLISH trial in the Lancet - The Lancet published in february 18, contained an article with further findings from the ACCOMPLISH trial. The following extract summarizes some of the findings: This trial shows that in patients with hypertension at high risk for cardiovascular events, combination treatment with Benazepril plus Amlodipine reduces progression of chronic kidney disease more effectively than does Benazepril plus Hydrochlorothiazide. This benefit was also seen when cardiovascular or all-cause mortality were assessed with progression of chronic kidney disease. Differences in blood pressure control throughout the study could not account for these findings. 
- February 20, 2010 - Biotech Sweden elects editorial council - Biotech Sweden, one of the Nordic countries most read news media, elects an editorial council. The council aims to act as advisors and gather information about everything that affects the life science industry. Among the elected is A+ Science CEO, Agneta Franksson. 
- December 11, 2008 - A+ Science accomplished yet another large important mortality-morbidity study - Results of the ACCOMPLISH* study were published December 4, 2008, in the New England Journal of Medicine. This study which is the first to compare Renin-Angiotensin-System (RAS) Inhibitor- based single-pill combinations in reducing cardiovascular complications showed exceptional blood pressure control and substantial further risk reduction for the benazepril/amlodipine vs Benazepril/diuretic combination. 
- October 8th, 2014 "A+ Science gets new co-workers" - Emelie Andersson, Andreas Jendeberg, Andreas Karnehed. Emelie Andersson joins the company as Safety Associate. Emelie carries the degree of Masters in Medical Science and has worked as a researcher within Preclinical R&D – in vivo pharmacology. She has a broad experience within local and global literature search. Andreas Jendeberg joins the company as Clinical Research Associate (CRA). Andreas is a pharmacist with experience from both the community pharmacies and the pharmaceutical industry. Andreas has worked as a Clinical Research Associate for the last couple of years, monitoring clinical studies throughout the Nordic Countries. Andreas Karnehed joins the company as Clinical Research Manager. Andreas has more than twelve years Research Manager. Andreas has more than twelve years of experience from the pharmaceutical industry. During the last eight years he has been working with clinical trials as Project Manager and Clinical Research Associate (CRA). He started his career in the pharmaceutical industry within the area of pharmacovigilance. He has worked with country project management of worldwide mega-trials within the cardiovascular area, as well as country project management within other therapeutic areas e.g. oncology, urology and women’s health. Andreas will strengthen the company’s in-house department for clinical trials.